GLP-1 stretch marks and injection sites: separating fact from TikTok lore

What did @countrycutie985 actually say?

She asked a practical, honest question: after years of pregnancy stretch marks, she struggled to find a clean injection site on her abdomen. "My stomach is like a roadmap," she said, describing the challenge of avoiding stretch marks while trying to rotate away from her usual arm sites. She wasn't making a medical claim. She was crowdsourcing a real-world problem that a lot of GLP-1 users share but rarely talk about.

To be clear, this video contains no dosing advice, no treatment claims, and no dangerous misinformation. It's a community question from someone who is clearly using GLP-1 medication under some form of guidance and running into a very common practical barrier. That context matters for how we evaluate what follows.

Does the science back this up?

The concern about injecting into or near stretch marks is legitimate, though the evidence is thinner than you'd hope. Most injection site guidance for subcutaneous GLP-1 medications, including semaglutide and tirzepatide, recommends avoiding areas with broken skin, scarring, or significant fibrotic tissue. Stretch marks (striae distensae) represent dermal scarring where collagen architecture is disrupted.

The practical worry is absorption variability. Subcutaneous drug absorption depends on local blood flow, adipose tissue depth, and tissue integrity. A 2020 review by Gradel et al. in Frontiers in Endocrinology documented that injection site characteristics, including lipohypertrophy and scarring, can meaningfully alter subcutaneous insulin absorption. While GLP-1 receptor agonists aren't insulin, they share the same subcutaneous delivery route and the same absorption dependency on tissue quality. There's no large randomized trial specifically on GLP-1 injection into stretch-marked skin, so extrapolation from insulin data is the best we have right now.

What did they get wrong (or right)?

She didn't get much wrong here, mostly because she wasn't making claims. She was asking questions. Credit where it's due: she correctly identified that rotating injection sites matters, and she was trying to do exactly that. Site rotation is a real clinical recommendation, not just a comfort preference. Injecting repeatedly into the same spot causes lipohypertrophy, and that's a documented problem for subcutaneous drug delivery.

What she didn't know, and couldn't have known from TikTok, is that the abdomen is generally still usable even with stretch marks, as long as you can find areas with adequate subcutaneous tissue depth and avoid active skin breakdown. The package inserts for semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) recommend the abdomen, thigh, or upper arm, but don't specifically address stretch marks. That guidance gap is a real problem, and her confusion is completely understandable given how little patient education addresses this scenario.

What should you actually know?

If you're using a subcutaneous GLP-1 medication and have significant abdominal stretch marks, a few things are worth knowing based on current clinical guidance and available evidence.

• Stretch marks alone don't automatically disqualify a site. Flat, stable striae without active inflammation or broken skin are different from raised, red, or freshly formed marks. The former is less likely to cause absorption issues than the latter.
• Subcutaneous depth matters more than surface texture. If there's adequate adipose tissue beneath the striae, absorption is more likely to be consistent. A 2019 study by Hauner et al. in Diabetes Technology and Therapeutics noted that adequate tissue depth is the primary predictor of reliable subcutaneous absorption.
• Thighs and upper arms are legitimate alternatives when the abdomen is compromised. Many patients find the outer thigh easier to manage with good tissue depth and fewer stretch marks.
• Ask your prescriber or pharmacist, not TikTok. This is exactly the kind of question that a telehealth consultation should answer, and it rarely does because providers don't always think to bring it up.

The broader point: postpartum bodies are underrepresented in GLP-1 clinical trial populations, and practical injection guidance for people with significant skin changes is genuinely underdeveloped. That's a gap in the medical literature, not a failure on her part.